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Abstract 
Understanding the Total lymphocyte count (TLC) and CD4 
relationship could aid design predictive instruments for making clinical 
decisions during antiretroviral therapy. The aim of this study was to 
determine the predictive ability of TLC for CD4 count less than or equal to 
350cells/mm3. 
A cross sectional study involving 432 HIV-I infected persons randomly 
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recruited from the HIV Clinics of Nnamdi Azikiwe University Teaching 
Hospital (NAUTH) Nnewi, NAUTH Oba and St Charles Borromeo Hospital 
Onitsha was conducted. Ethical approval was obtained and blood samples 
were collected. The following were determined; HIV- screening and 
confirmation using serial testing algorithm with ELISA rapid test kits, CD4 
count using Cyflow partec machine and Haematological profile using 
Sysmex KX21N. Data analysis was carried out using SPSS version 17. 
Out of the 432 HIV patients involved in this study, females dominated with a 
population of 274(63.4%) against the males numbering 158(36.6%). The 
relationship between the TLC cut offs and CD4 count ≤350 cells/mm3 were 
all statistically significant (P<0.05) except for a TLC value of 2600cells per 
mm3. At a value of 1200 cells/mm3, TLC had a sensitivity of 25% and 
specificity of 96% while at 2400 cells/mm3, TLC had a sensitivity of 76% 
and specificity of 39% for CD4 count of ≤350cells/mm3.TLC was found to 
have the most significant relationship with CD4 count of all parameters 
tested using regression analysis. Finally, TLC could serve as a surrogate for 
CD4 count for monitoring treatment in resource poor areas where facilities 
for CD4 count may not be available.  
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Introduction 
The Total lymphocyte count are associated with disease progression 
in patients with AIDS (Aupril et al, 2008) and the World Health organization 
has suggested that they could be used as markers to initiate highly active 
antiretroviral therapy (HAART) in resource- poor settings( WHO, 2004) 
.Plasma HIV RNA levels and CD4+ lymphocyte counts are established 
markers of HIV disease progression and quantify an individual’s risk for 
AIDS and death. Obtaining CD4+ cell counts and HIV RNA levels may be 
impractical for countries with scarce resources, due to the expense of assays 
and technical factors such as access to the proper equipment(Beck et al, 
1996). Therefore there is a need for prognostic markers that can be used in 
resource limited settings. One marker that may fulfill this need is the Total 
lymphocyte count (TLC). It is relatively inexpensive and straightforward to 
measure. TLC has been shown to correlate with CD4+ cell counts, 
particularly among symptomatic individuals (Beck et al, 1996) and single 
measurements have been shown to have some prognostic information for 
survival and progression to AIDS (Schechter et al, 1994). Furthermore, 
world health organization guidelines for developing countries (WHO, 2002) 
suggest the use of TLC for disease monitoring if CD4+ cell counts are not 
known. Currently the WHO has adjusted to a CD4 count level of 
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350cells/mm3 before initiating treatment(WHO, 2010) ,there was need 
therefore to revise the TLC cut-off for CD4 Count <350cell/mm3. In Nigeria, 
the Federal Ministry of Health now commences  ART in all patients with 
HIV infection who have a CD4+cell count ≤350 cells/mm3 including 
pregnant women irrespective of clinical symptom. Inaddition, ART is started 
in all patients with WHO clinical stage 3 or 4 irrespective of CD4 
count(FMH, 2010)..  
Materials and Methods 
Study Design 
A cross sectional study was conducted among 432 HIV-I infected 
persons (158 males and 274 females), randomly recruited from the HIV 
Clinics of Nnamdi Azikiwe University Teaching Hospitals Nnewi, Oba  and 
St Charles Borromeo hospital Onitsha. Of these, 181 were drug naïve and 
251 drug experienced . Ethical consideration was obtained from the Ethical 
committee of both hospitals. Informed consent was obtained from the 
patients after which they were served questionnaire. Questionnaires were 
accurately filled and the following data obtained; personal factors like age, 
gender, type of antiretroviral drug administered and number of years on 
drug. Five milliliters of blood samples were collected using EDTA 
anticoagulant bottles The following parameters were performed for each 
participant; HIV- screening and  confirmation, CD4 count and  
Haematological profile. 
Inclusion Criteria 
1. HIV-I infected on HAART therapy for atleast I year period (for 
drug experienced group)                           
2. HIV infected but not on drugs (for drug naïve participants) 
3. Age range of 15-70 years 
Exclusion Criteria 
1. Patients were excluded if they test negative to HIV-I. 
2. If they are drug experienced but duration is less than 1 year. 
3. Pregnant women (After performing a pregnancy test for those not 
visibly pregnant and excluding those visibly pregnant). 
Study Area 
The study area was Nnewi, Oba and Onitsha all in Anambra state 
Nigeria.These towns are located within the tropical rain forest. They are both 
commercial towns. While Onitsha is located beside the popular river Niger, 
Oba lies 7kilometers south of Onitsha and Nnewi is located east of river 
Niger and 22kilometers from Onitsha. 
Calculation Of Sample Size 
Sample size was calculated using the minimum sample size for 
simple proportion with 5% margin of error and 95% level of confidence as 
shown below. Equally, a monthly prevalence rate (P) was obtained from the 
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HIV clinic of the Nnamdi Azikiwe University Teaching Hospital Nnewi  and 
St Charles Borromeo hospital Onitsha. 
N=Z2PQ/D2 
Where Z= Standard normal deviation at 1.96(which corresponds to 
95% confidence interval). 
P= Monthly Sero prevalence of HIV infection in HIV clinic attendees 
=16% 
Q=1-P 
D=Degree of accuracy/ precision expected = 0.05% 
Substituting for the above formulae  
N=1.962x(0.16x0.84)/(0.05)2    =   206  . 
Sampling Procedure And Sample Size 
The sample size for the study was 432 patients. The patients were 
recruited using stratified random sampling technique by drawing the sample 
frame of the patients which consist of antiretroviral drug experienced stratum 
and antiretroviral drug naïve stratum; 251 and 181 patients were randomly 
selected from each stratum respectively using probability by replacement 
method. 
HIV Counselling And Testing Procedure 
The nature of the research was explained to each participant after 
which informed consent was sought. Subsequently, the participants were 
presented with the informed consent form and they consented to it. Only 
patients who gave their consent were included in the study and they were 
assured of confidentiality and freedom of withdrawal. HIV testing was 
performed after pre test counseling and also post test counseling took place 
after the testing by trained HIV counselors, according to National AIDS 
programs guidelines. The investigation was performed according to standard 
laboratory practice and followed guidelines approved by National HIV Rapid 
test Algorithm. Rapid testing was done using Determine, Unigold and Stat 
Pak. The results obtained were analyzed statistically using the SPSS version 
17. 
Methods 
HIV Rapid Testing 
The rapid HIV test kits consisting of 3 different antigens were used 
for the diagnosis of HIV infection by serial testing algorithm. The first test 
was performed using Determine kit (Abbott Laboratories, USA) (screening 
test) and if positive a second test is performed using Unigold( Trinity 
Biotech, Ireland), if positive the patient is considered positive for HIV but if 
negative, the third test which acts as tie breaker is carried out using Stat pak 
(Chembio Diagnostic System, USA).  
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CD4 Count 
The CD4+ T cell count was done to determine the level of immune 
function. The Cyflow Partec machine (Partec GmbH, Munster, Germany) 
were used. The Cyflow detects and identifies fluorochrome- labeled 
(phytoerythrin, PE) cells as they pass through an optical detecting system by 
detecting the angle of scatter of incident laser and the wavelength of 
fluorescence emitted. Twenty microlitres of patient’s blood was added to 
20µl of PE antibody in Rohren tube. This was adequately mixed and 
incubated in the dark for 15mins at room temperature. Exactly, 800µl of the 
buffer was then added to the tube and mixed adequately. The sample tube 
was plugged onto the sample port of the Cyflow machine for counting of the   
CD4 + T cells. The monitor displayed the result of the counting and this was 
recorded as the number of cells/µl of blood. 
Assessment Of Haematological Profile Using The Sysmex Kx 21n Auto 
Analyzer 
White Blood Cell/ Haemoglobin Analysis 
Here,the volume of WBC and HB in the blood were measured . 
Blood was aspirated from the sample probe into the sample rotor valve. Six 
microlitre of blood measured by the sample rotor valve was transferred to the 
WBC transducer chamber along with 1.994ml of diluents. At the same time, 
I added 1.0ml of WBC /HB lyse to prepare 1:500 dilution of sample. The 
solution was made to react in this status for approximately 10 seconds, RBC 
was then hemolysed and platelet shrunk, with WBC membrane held as they 
are.  At the same time, haemoglobin was converted into red coloured 
methaemoglobin. Of the diluted/ hemolysed sample in the WBC transducer 
chamber, approximately 1ml was transferred to the HB flow cell. Five 
hundred microlitre of sample in the WBC transducer was aspirated through 
the aperture. The pulses of the blood cells when passing through the aperture 
were counted by the DC detection method. In the HB flow cell, 555nm 
wavelength beam irradiated from the light emitting diode(LED) was applied 
to the sample in the HB flow cell. Concentration of this sample was then 
measured as absorbance. This absorbance was compared with that of the 
diluents alone that was measured before addition of the sample, thereby 
calculating HB . 
Red Blood Cell And Platelet Analysis 
In RBC and platelet analysis, RBC and Platelet count in the blood 
were measured. Here, I aspirated blood   from the sample probe into the 
sample rotor valve. Then 4uL of blood measured by the sample rotor valve 
was diluted into 1:500 with 1.996ml of diluents and brought to the mixing 
chamber as diluted sample . Out of the 1:500 dilution sample, 40uL was 
measured by the sample rotor valve, diluted into 1:25000 with 1.960ml of 
diluent, then transferred to the RBC/ platelet transducer chamber. 
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Subsequently, 250uL of the sample in the RBC/platelet transducer was 
aspirated through the aperture. At this time, RBC and platelet are counted by 
the DC detection method. At the same time, haematocrit value was 
calculated by the RBC pulse height detection method. 
Results 
Table 1:  Age Distribution Of Hiv Infected Individuals According To Sex And Drug 
Use 
 
AGE 
YEARS 
 
DRUGS 
 
P-VALUE 
 
 
 
SEX 
 
P-VALUE 
 
 
 
EXPERIENCED 
NO (%) 
 
NAÏVE 
NO (%) 
 
MALE 
NO (%) 
 
FEMALE 
NO (%) 
       
<25 49(19.5) 32(17.7)  
 
0.032 
27(17.1) 54(19.7)  
 
0.239 
25-44 88(35.1) 87(48.1) 62(39.2) 113(41.2) 
45-64 112(44.6) 62(34.3) 67(42.4) 107(39.1) 
>64 2(0.8) 0(0) 2(1.3) 0(0) 
TOTAL 251(100) 181(100) 158(100) 274(100) 
Results are presented as Means ± S.D. P is significant at P≤0.05 
 
Table 2: Sensitivity, Specificity, Positive And Negative Predicitive Values Of Tlc Cut Offs 
For Cd4 Count ≤ 350 Cells/Mm3 
 
CD4 COUNT 
(CELLS/MM3) 
N=432 
 
TLC 
CUT 
OFF 
 
P-VALUE 
 
SENSITIVITY (%) 
 
SPECIFICITY (%) 
 
PPV 
(%) 
 
NPV 
(%) 
 
 
≤350 
 
1200 
 
0.000 
 
25 
 
96 
 
89 
 
48 
1400 0.000 33 89 81 49 
1600 0.000 43 83 78 51 
1800 0.000 52 77 76 53 
2000 
2200 
2400 
2600 
0.000 
0.000 
0.001 
0.83 
62 
69 
76 
80 
64 
49 
39 
27 
70 
65 
63 
60 
55 
54 
53 
49 
Results are presented as Means ± S.D. P value is significant at P<0.05 
• PPV refers to positive predictive value 
• NPV refers to negative predictive value 
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Discussion 
CD4 testing is the recognized gold standard used to stage HIV/AIDS, 
guide treatment decisions for HIV-infected persons and evaluate 
effectiveness of therapy. The need for a less expensive surrogate marker that 
can be used in resource-limited setting is however necessary. This study 
which consisted of 432 participants with  181 drug naïve and 251 drug 
experienced sought to assess the suitability of Total lymphocyte count (TLC) 
as a surrogate marker for CD4 count in resource-limited localities. An 
attempt to use TLC as a surrogate for CD4 count was made in table two. The 
WHO has advised that in resource poor areas where routine CD4 count is not 
readily available, the TLC can be used as an alternative (WHO,2004).The 
World Health Organization (WHO) currently recommends that adults living 
with HIV start antiretroviral therapy (ART) when their CD4 counts fall 
below 350 cells/µl as against 200cells/mm3 (WHO, 2010). There was need 
therefore to revise the TLC cut-off for CD4 Count ≤350cell/mm3.  Here, 
various values of CD4 cut offs were tested against a CD4 count ≤350 
cells/mm3. These includes TLC of (1200, 1400, 1600, 1800, 2000, 2200, 
2400 and 2600) cells/mm3. The relationship between the different TLC cut 
offs and CD4 count ≤350 cells/mm3 were all statistically significant with 
P<0.05 except  at TLC level of 2600cells/mm3 with P>0.05. At a value of 
1200 cells/mm3, TLC had a low sensitivity of 25% and the highest 
specificity of 96%. It also had the highest positive predictive value of 89% 
and lowest negative predictive value of 48% at the 1200 cells/mm3 cut off 
for TLC. The sensitivity of the different TLC cut offs have an inverse 
relationship with the specificity. Therefore at a TLC value of 2400 
cells/mm3, TLC had a high sensitivity of 76% and specificity of 39%. At a 
TLC level of 2600cells/mm3 there was no significant relationship between 
TLC and CD4 count of ≤350cells/mm3 (P>0.05). This shows that TLC 
values of 2600cells/mm3 and greater  may not be useful in monitoring CD4 
count of ≤350cells/mm3 .The present study shows that a TLC range of 1200-
2400 cells/mm3 could predict CD4 ≤350 cells mm−3 but this will serve a 
better purpose in the management and monitoring of HIV patients if a 
calibration cut-off could be established in our local settings. This in addition 
to WHO clinical stage of disease, haemoglobin and weight could serve as 
useful model in resource poor setting.The value of TLC as a surrogate for 
CD4 in monitoring HIV disease in the absence of viral loads and CD4 counts 
has been argued (Crowe et al, 2003) but current WHO guidelines only 
commit to using TLC in conjunction with clinical data as a criterion to 
initiate HAART in resource poor settings (WHO,2006). In a work carried out 
by Mwangi et al, 2011, in Kenya, they found that Of 362 HIV positive 
pregnant women, 160(44.5%) had CD4 count <350 cells/mm3. Using linear 
regression optimal cut-off points for TLC, HB, BMI were 850cell/mm3, 
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8.4g/dl and 15.5kg/m2 respectively. These cut-off points were highly specific 
but with very low sensitivity. The best cut-off point using generated 
sensitivity and specificity values was TLC≤2200 with Sensitivity of 68% and 
Specificity of 51%.  
Regression line graphs of predictive parameters for CD4 count are 
shown in the figures above. In this assessment, a regression line graph was 
drawn to ascertain the level of relationship between CD4 count and WBC, 
HB, TLC, Neutrophil, HCT and Platelet. TLC was found to have the most 
significant relationship with CD4 count (Fig. 1), with P value of 0.000 and 
for every unit increase in TLC, there is a 1.002 increase in CD4 count. WBC 
(Fig 6) and Platelet (Fig 5) had no significant relationships with CD4 count 
with P values of 0.972 and 0.636 respectively. HB, Neutrophil and HCT also 
gave significant relationships with CD4 count with P values of 0.000, 0.000, 
0.000 and 0.000 respectively .This shows that TLC compares most favorably 
with CD4 count and may serve as a surrogate for it. In a similar pattern, a 
linear regression model was conducted by Owiredu et al, 2011, to assess the 
ability of some selected study parameters to predict CD4 counts in HAART-
naïve patients and those on HAART. It was observed that for unit increases 
in CD4 as an independent variable, there were corresponding unit increases 
in TLC, lymphocyte count, haemoglobin and weight. There was no linear 
relationship between total white blood cell count and CD4 count and platelet 
count showed a negative relationship. The ability of TLC, lymphocyte count, 
haemoglobin and weight to predict CD4 count in both HAART-naïve 
patients and those on HAART suggests that these parameters which are 
relatively inexpensive and easily available compared to techniques for 
assaying CD4 and viral load could serve as accurate tools that can be used 
for monitoring the patients' immune status during therapy in addition to 
determining when patients should start antiretroviral therapy. Mwamburi et 
al., 2005, reported a similar finding and suggested modification of the 
models to suit specific needs for use in underserved areas. Finally, TLC 
could serve as a surrogate for CD4 with effective clinical staging of disease, 
inclusion of haemoglobin level, weight values and appropriate calibration of 
TLC cutoffs to suit local requirement. 
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